Commitments and Contingencies - License Agreements - Additional Information (Details) - TMRC - USD ($) |
1 Months Ended | 3 Months Ended | 9 Months Ended | |||
---|---|---|---|---|---|---|
Sep. 30, 2016 |
May 31, 2016 |
Sep. 30, 2015 |
Sep. 30, 2020 |
Sep. 30, 2020 |
Sep. 30, 2019 |
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||
Up-front license fee | $ 1,000,000.0 | |||||
Payment of up-front license fee | $ 500,000 | 500,000 | ||||
Payments per indication due upon the successful achievement of clinical and regulatory milestones | $ 13,000,000.0 | |||||
Payments made upon achievement of development milestone | $ 1,000,000.0 | |||||
Fees incurred under supply management agreement | $ 0 | $ 800,000 | $ 0 |
X | ||||||||||
- Definition Payments made per the license agreement, for a development milestone achieved. No definition available.
|
X | ||||||||||
- Definition The payments per indication due upon the successful achievement of clinical and regulatory milestones. No definition available.
|
X | ||||||||||
- Definition Represents fees incurred under the supply management agreement. No definition available.
|
X | ||||||||||
- Definition Represents the amount of the up-front license fee. No definition available.
|
X | ||||||||||
- Definition Represents the amount of the up-front license fee payments made during the period. No definition available.
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Details
|